ArticleDrug design, development and therapy2025
Targeting CD20 in Primary Membranous Nephropathy Serologically and Histologically Negative for PLA2R: Is Obinutuzumab Superior to Rituximab?
Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Contemporary review of primary membranous nephropathy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Anti-CD20 monoclonal antibody has become the first-line treatment option for primary membranous nephropathy (PMN), regardless of PLA2R status. Obinutuzumab (OBZ), a humanized anti-CD20 monoclonal antibody, has shown higher remission rates with an acceptable safety profile over rituximab (RTX), whether in the initial treatment or refractory PLA2R-associated membranous nephropathy. However, the efficacy evaluation of the OBZ and RTX in PLA2R-negative PMN has not been reported yet. Methods: 39 patients with PMN who were negative for serum anti-PLA2R antibodies and showed negative PLA2R staining in renal biopsy were retrospectively included in this study, with 18 receiving OBZ and 21 receiving RTX. All patients received a 12-month follow-up. The primary outcome was the rate of patients achieving complete or partial remission (CR or PR) at 12 months. Secondary outcomes included changes in laboratory parameters, relapse, and adverse events. Results: At 12 months, CR or PR was achieved in 17 of 18 (94.4%) patients in the OBZ group and 18 of 21 (85.7%) patients in the RTX group, with the difference between the two groups not being statistically significant (OR=2.83, 95% CI: 0.27-29.96; Conclusion: In patients with PLA2R-negative PMN, OBZ demonstrated similar efficacy to RTX, and both had a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.